Analyst consensus rating
Biodexa Pharmaceuticals Analyst Rating: none
BDRX is rated none by 1 analysts with a $10.23 target. As of 2026-08-19.
Direct answer
Biodexa Pharmaceuticals's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $10.23.
Forecast evidence checked August 19, 2026.
Get free Biodexa Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.39
- Average price target
- $10.23
- High price target
- $10.23
- Low price target
- $10.23
- Low target gap
- +636%
- Target upside
- +636%
- High target gap
- +636%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- August 19, 2026
- Valid through
- August 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Biodexa Pharmaceuticals?
Biodexa Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $10.23.
How far are Biodexa Pharmaceuticals's low and high targets from the recorded price?
The low target implies +636%, while the high target implies +636%.
How many analysts are included in Biodexa Pharmaceuticals's consensus?
The verified consensus includes 1 analysts.
How is Biodexa Pharmaceuticals's target upside or downside calculated?
The average target of $10.23 is divided by the recorded price of $1.39, then one is subtracted to produce +636%. This does not guarantee a future return.
When was Biodexa Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-19. The dataset is valid through 2026-08-26.